Safety and Immunogenicity of a <i>Klebsiella pneumoniae</i> Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I/II Randomized and Controlled Study

Cristina Alaimo(Spital Limmattal), Patricia Martín(University of California, Los Angeles)

The Journal of Infectious Diseases

November 22, 2025

10.1093/infdis/jiaf600

Cited by 3

Related Papers

Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial

|The Lancet Infectious Diseases|2017|209